InnerMost Launches to Evolve Psychedelic Therapy – Advancing Treatment, Access, and Knowledge in the Field

Uniting FDA-authorized trials, ketamine and Spravato therapy, therapist training, and community education under one roof, InnerMost brings a vital new resource, contributing to the field globally

NEW YORK, NY / ACCESS Newswire / November 21, 2025 / InnerMost PBC, New York City’s new psychedelic-assisted therapy center dedicated to accessible care, practitioner training, FDA-authorized clinical trials, and community building, is officially open.

A public benefit corporation, InnerMost provides accessible ketamine and Spravato therapy, is an FDA-trial site that trains psychedelic-assisted therapists, and builds community amongst clinicians in this paradigm-shifting field.

With mental health needs at an all-time high, and uncertainty across politics and research, its launch introduces a hub for evidence-based psychedelic care-supporting New Yorkers while advancing access and progress globally. New hope emerges as the mainstream embraces new evidence-based approaches that expand what’s possible in mental health care.

Leading conversations about psychedelic therapy’s past, present and future is Casey Paleos, MD, (CV) Co-Founder & Chief Medical Officer, board-certified psychiatrist and researcher with 15+ years in psychedelic-assisted therapy. As figures like Rick Doblin pass the baton, they sing praises about his body of work and vision:

• Read moreFossil launches its first smartwatch on the Qualcomm Snapdragon Wear 3100 platform

  Principal Investigator, MAPS MDMA therapy for PTSD Studies

• Therapist, NYU Psilocybin Cancer Anxiety Study

• Co-Founder, Nautilus Sanctuary

• Founding Board Member, International Alliance of MDMA Practitioners

• Presenter, “Understanding Ketamine” Workshop, Psychotherapy Networker conference, Washington, D.C.

• Read moreConwy Care Home Multi-Professional Response wins Secure I.T. Environments Sponsored award at Betsi Cadwaladr University Health Board Achievement Awards

  Co-Author of “Inner-Directed Therapy in MDMA-Assisted Psychotherapy,” newly released commentary on the MDMA debate in the American Journal of Psychiatry

WHY INNERMOST IS DIFFERENT:

• Research:FDA-authorized clinical trial site, including ongoing MDMA research and more TBA.

• Treatment: Integration of psychotherapy with ketamine, Spravato, and future integrative mental health modalities.

• Training: Practicum training, mentorship and clinical supervision.

• Read moreTorus and Aareon Collaborate on Housing Management Solution

  Education & Community: Public programming, podcasts, panels, and partnerships.

• Accessibility: Public benefit corporation whose mission is to eliminate socioeconomic barriers to accessing psychedelic therapies.

VISUALS:

• First look at InnerMost’s space and design.

• Interviews with Dr. Paleos and team.

• Photo and video opportunities.

Now open to the public by appointment at innermost.one, media are invited to schedule private tours of InnerMost.

MEDIA CONTACT: Marissa Feinberg | marissa@triplebottomwhy.com | 917-494-5041

SOURCE: InnerMost

View the original press release on ACCESS Newswire